Therapeutic agent

Paxlovid (Nirmatrelvir + Ritonavir)

Also known as: Paxlovid (Nirmatrelvir + Ritonavir)

ModerateEvidence level
5Registered trials
1Conditions
2Study references

Evidence Summary

Evidence Level
Moderate
Mechanism
Antiviral / Persistence, Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Network
Safety
Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing
See linked studies/trials for reported doses and durations; typical protocols vary widely.
Investigational for listed conditions. 5 associated trial(s) and 3 study reference(s) in current data. Review primary sources and consult specialists before use.

Clinical Trials

5 trial(s) registered

NCT IDTitlePhaseStatus
NCT07597902SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID DysfunctionPhase 2Not yet recruiting
NCT05965726RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID SymptomsPhase 2Completed
NCT05595369RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID SymptomsPhase 2Completed
NCT05852873PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in NorwayPhase 3Active, not recruiting
NCT05576662Paxlovid for Treatment of Long CovidPhase 2Completed

Key Studies / References